Johnson & Johnson (JNJ) — closed signal from December 29, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on March 29, 2026 — +15.3% at the close.
Predicted vs. what happened
What happened
Reached its target in 31 days.
The thesis — published December 29, 2025
Johnson & Johnson is a defensive healthcare company that just agreed to buy Halda Therapeutics for $3.05 billion. The deal shows they are still building new products, which makes the stock a steadier choice in a weak market. The trade is about reducing risk and possibly getting a modest rebound after a period of selling, not chasing fast growth.
Primary drivers
- Halda deal gives a clear, near-term business story
- Healthcare status makes it relatively stable in weak markets
- Big, varied sales lower risk from one product failing
- Historically small swings help protect overall portfolios
How it played out
JNJ: target reached in 31 days
Lyra published JNJ at $208.54 on 2025-12-29, with 10% expected growth over a short-term window. The thesis pointed to Johnson & Johnson as a defensive healthcare company, the Halda Therapeutics deal for $3.05 billion, broad sales, steadier trading, and a possible modest rebound after selling.
Inside the window, the stock reached the $229.39 target in 31 days. It kept rising to a peak of $251.71 on 2026-03-02, a 20.7% gain. By 2026-03-29, it ended at $240.45, still above the target. The thesis played out.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.